Rigel Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.01.25	Rigel Pharma: FDA Grants Orphan Drug Designation To R289 - Quick Facts (RTTNews)
07.11.24	Rigel Pharmaceuticals Inc. Q3 Earnings Summary (RTTNews)
03.09.24	Kissei Expands Relationship With Rigel To Commercialize Olutasidenib In Japan, Korea, Taiwan (RTTNews)
06.08.24	Rigel Pharmaceuticals Inc. Q2 Loss Decreases, Beats Estimates (RTTNews)
07.05.24	Rigel Pharmaceuticals Inc. Q1 Loss decreases, but misses estimates (RTTNews)
06.05.24	Ausblick: Rigel Pharmaceuticals präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
12.03.24	Rigel Pharma Names Rojkjaer EVP, Chief Medical Officer (RTTNews)
05.03.24	Rigel Pharmaceuticals Inc. Q4 Earnings Summary (RTTNews)
04.03.24	Ausblick: Rigel Pharmaceuticals stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
22.02.24	Rigel Pharma Acquires US Rights To Gavreto From Blueprint Medicines; Stock Up In Pre-Market (RTTNews)
08.01.24	Rigel Pharmaceuticals Expects 2023 Net Product Sales To Rise 36% - Quick Facts (RTTNews)
04.01.24	Rigel Pharma Collaborates With CONNECT To Conduct Phase 2 Trial Of Olutasidenib In Glioma (RTTNews)
08.12.23	Rigel Pharma Enters Alliance With MD Anderson To Evaluate REZLIDHIA - Quick Facts (RTTNews)
08.12.23	Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers (PR Newswire)
07.11.23	Rigel Pharmaceuticals Inc. Q3 Loss decreases, beats estimates (RTTNews)
07.11.23	Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
06.11.23	Rigel to Present at the Jefferies London Healthcare Conference (PR Newswire)
06.11.23	Ausblick: Rigel Pharmaceuticals gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
02.11.23	Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
31.10.23	Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update (PR Newswire)
11.10.23	Rigel Announces Presentation at the Upcoming IDWeek 2023 (PR Newswire)
20.09.23	Rigel to Present at the 2023 Cantor Global Healthcare Conference (PR Newswire)
30.08.23	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire)
01.08.23	Rigel Pharmaceuticals Inc. Q2 Loss decreases, beats estimates (RTTNews)
01.08.23	Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
31.07.23	Ausblick: Rigel Pharmaceuticals informiert über die jüngsten Quartalsergebnisse (finanzen.net)
07.06.23	Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML (PR Newswire)
06.06.23	Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances (PR Newswire)
01.06.23	Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting (PR Newswire)
31.05.23	Rigel to Present at the Jefferies 2023 Global Healthcare Conference (PR Newswire)
02.05.23	Rigel Pharmaceuticals Inc. Q1 Loss decreases, beats estimates (RTTNews)
02.05.23	Rigel Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
01.05.23	Ausblick: Rigel Pharmaceuticals öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
08.03.23	Pre-market Movers: FRTX, RIGL, INBS, MAXN, CVM… (RTTNews)
07.03.23	Rigel Pharmaceuticals Inc. Q4 Earnings Summary (RTTNews)
07.03.23	Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (PR Newswire)
06.03.23	Ausblick: Rigel Pharmaceuticals legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
02.02.23	Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances (PR Newswire)
18.01.23	National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia (PR Newswire)
09.01.23	Rigel Pharmaceuticals Expects Q4 Revenue To Surge (RTTNews)
09.01.23	Rigel Pharmaceuticals Provides Business Update (PR Newswire)
22.12.22	Rigel Launches AML Treatment REZLIDHIA (RTTNews)
22.12.22	Rigel Pharma Launches Rezlidhia In U.S. For Relapsed Acute Myeloid Leukemia With IDH1 Mutation (RTTNews)
22.12.22	Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation (PR Newswire)
15.12.22	Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes (PR Newswire)
02.12.22	Rigel : FDA Oks REZLIDHIA For Treatment Of R/R Acute Myeloid Leukemia With Susceptible IDH1 Mutation (RTTNews)
01.12.22	Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation (PR Newswire)
10.11.22	Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology (PR Newswire)
03.11.22	Rigel Pharmaceuticals Inc. Q3 Loss decreases, beats estimates (RTTNews)
03.11.22	Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Rigel Pharmaceuticals IncShs

Aktien Top/Flop

Meistgelesene Nachrichten